JP2009537542A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537542A5
JP2009537542A5 JP2009511057A JP2009511057A JP2009537542A5 JP 2009537542 A5 JP2009537542 A5 JP 2009537542A5 JP 2009511057 A JP2009511057 A JP 2009511057A JP 2009511057 A JP2009511057 A JP 2009511057A JP 2009537542 A5 JP2009537542 A5 JP 2009537542A5
Authority
JP
Japan
Prior art keywords
pyrrolidin
dimethylamino
carbonyl
phenyl
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009511057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011765 external-priority patent/WO2007136668A2/en
Publication of JP2009537542A publication Critical patent/JP2009537542A/ja
Publication of JP2009537542A5 publication Critical patent/JP2009537542A5/ja
Withdrawn legal-status Critical Current

Links

JP2009511057A 2006-05-19 2007-05-16 ヒスタミン−3アンタゴニストとしてのn−ベンゾイルピロリジン−3−イルアミンおよびn−ベンジルピロリジン−3−イルアミン Withdrawn JP2009537542A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80190506P 2006-05-19 2006-05-19
PCT/US2007/011765 WO2007136668A2 (en) 2006-05-19 2007-05-16 N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists

Publications (2)

Publication Number Publication Date
JP2009537542A JP2009537542A (ja) 2009-10-29
JP2009537542A5 true JP2009537542A5 (enExample) 2010-07-08

Family

ID=38616614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511057A Withdrawn JP2009537542A (ja) 2006-05-19 2007-05-16 ヒスタミン−3アンタゴニストとしてのn−ベンゾイルピロリジン−3−イルアミンおよびn−ベンジルピロリジン−3−イルアミン

Country Status (12)

Country Link
US (1) US7842715B2 (enExample)
EP (1) EP2027086B1 (enExample)
JP (1) JP2009537542A (enExample)
CN (1) CN101432261A (enExample)
AR (1) AR061015A1 (enExample)
AT (1) ATE533744T1 (enExample)
AU (1) AU2007254232A1 (enExample)
CA (1) CA2649913A1 (enExample)
MX (1) MX2008014743A (enExample)
PE (1) PE20080371A1 (enExample)
TW (1) TW200811165A (enExample)
WO (1) WO2007136668A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530274A (ja) * 2006-03-15 2009-08-27 ワイス ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US20100063047A1 (en) * 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
US20130245064A1 (en) * 2010-11-01 2013-09-19 Shaheen Ahmed Novel neurotrypsin inhibitors
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102784146A (zh) * 2011-05-19 2012-11-21 复旦大学 N-苯基喹唑啉-4-胺类衍生物的药用用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
CN1052224C (zh) 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
CA2287984A1 (en) 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
CA2298813A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
PL192083B1 (pl) * 1997-11-18 2006-08-31 Dupont Pharmaceuticals Res Lab Pochodne amin cyklicznych i ich zastosowanie
PL345283A1 (en) 1998-07-20 2001-12-03 Merck Patent Gmbh Biphenyl derivatives
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
US20030149038A1 (en) 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1569905A2 (en) 2002-12-06 2005-09-07 Eli Lilly And Company Inhibitors of monoamine uptake
PT1603917E (pt) 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
WO2006019833A1 (en) 2004-07-26 2006-02-23 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
US7705025B2 (en) 2004-08-23 2010-04-27 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1848696A1 (en) 2005-01-21 2007-10-31 Schering Corporation Imidazole and benzimidazole derivates useful as histamine h3 antagonists
EP1847532B1 (en) 2005-01-27 2013-06-05 Kyowa Hakko Kirin Co., Ltd. Igf-1r inhibitor
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ,インコーポレイテッド ブラジキニンb1受容体拮抗作用に有用な新規化合物
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物
EP1996555A1 (en) 2006-03-20 2008-12-03 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Similar Documents

Publication Publication Date Title
JP2005526723A5 (enExample)
CN105051005B (zh) 环丙胺化合物及其用途
CN101426774B (zh) 唑类甲酰胺衍生物
NZ616828A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6600388B2 (ja) P2x4受容体拮抗剤
RU2012129737A (ru) Замещенные бензамидные производные
JP2017522346A5 (enExample)
TWI465439B (zh) 三氮唑衍生物或其鹽
JP2022549222A5 (enExample)
JP2005524609A5 (enExample)
JP2013056930A5 (enExample)
JP2018511587A5 (enExample)
JP2010506918A5 (enExample)
JP2019505595A5 (enExample)
JP2012515724A5 (enExample)
JP2017530185A5 (enExample)
NZ593594A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2018529770A5 (enExample)
JP7330546B2 (ja) 癌細胞の成長を抑制するピリミジン誘導体およびその医薬用途
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2021535112A5 (enExample)
JP2022511477A5 (enExample)
JP2013530957A5 (enExample)
JP2010526867A5 (enExample)